[
    {
     "kind": "calendar#event",
     "etag": "\"3315261612290000\"",
     "id": "0a649i6ikrri9s0h83tuo1uh0k",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=MGE2NDlpNmlrcnJpOXMwaDgzdHVvMXVoMGsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-07-12T13:00:06.000Z",
     "updated": "2022-07-12T13:00:06.145Z",
     "summary": "ARQT Arcutis Biotherapeutics, Inc. PDUFA",
     "description": "2023-04-30 The target action date is April 30, 2023. https://www.globenewswire.com/news-release/2022/07/11/2477212/0/en/Arcutis-Biotherapeutics-Announces-Health-Canada-Accepts-for-Review-the-New-Drug-Submission-for-Roflumilast-Cream-for-Adults-and-Adolescents-with-Plaque-Psoriasis.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-04-30"
     },
     "end": {
      "date": "2023-04-30"
     },
     "iCalUID": "0a649i6ikrri9s0h83tuo1uh0k@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3328912806846000\"",
     "id": "o448v8jtnrmpa59j75mpl865bk",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bzQ0OHY4anRucm1wYTU5ajc1bXBsODY1YmsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-09-29T13:00:03.000Z",
     "updated": "2022-09-29T13:00:03.423Z",
     "summary": "PHAR Pharming Group N.V. PDUFA",
     "description": "2023-03-29 The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification. https://www.prnewswire.com/news-releases/pharming-announces-us-fda-acceptance-for-priority-review-of-its-new-drug-application-for-leniolisib-301634867.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-03-29"
     },
     "end": {
      "date": "2023-03-29"
     },
     "iCalUID": "o448v8jtnrmpa59j75mpl865bk@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3332196006858000\"",
     "id": "ujgp9pna32kd5e4r07dpl7iup0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=dWpncDlwbmEzMmtkNWU0cjA3ZHBsN2l1cDAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-10-18T13:00:03.000Z",
     "updated": "2022-10-18T13:00:03.429Z",
     "summary": "BIIB Biogen Inc. PDUFA",
     "description": "2023-04-25 The updated Prescription Drug User Fee Act (PDUFA) goal date is April 25, 2023. https://www.globenewswire.com/news-release/2022/10/17/2535365/0/en/Biogen-Announces-FDA-s-3-Month-Extension-of-Review-Period-for-the-New-Drug-Application-for-Tofersen.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-04-25"
     },
     "end": {
      "date": "2023-04-25"
     },
     "iCalUID": "ujgp9pna32kd5e4r07dpl7iup0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3333751206044000\"",
     "id": "abfbbed086se1mfrdfu7tqgcd4",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=YWJmYmJlZDA4NnNlMW1mcmRmdTd0cWdjZDQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-10-27T13:00:03.000Z",
     "updated": "2022-10-27T13:00:03.022Z",
     "summary": "MCRB SERES THERAPEUTICS, INC. PDUFA",
     "description": "2023-04-26  PDUFA target action date is April 26, 2023, with anticipated launch soon thereafter  http://www.businesswire.com/news/home/20221026005415/en/Seres-Therapeutics-Announces-FDA-Acceptance-of-Biologics-License-Application-for-Investigational-Microbiome-Therapeutic-SER-109-for-Recurrent-C.-Difficile-Infection-for-Priority-Review",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-04-26"
     },
     "end": {
      "date": "2023-04-26"
     },
     "iCalUID": "abfbbed086se1mfrdfu7tqgcd4@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3334615218546000\"",
     "id": "dcl2i1qi6bomu783laekelu2ik",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ZGNsMmkxcWk2Ym9tdTc4M2xhZWtlbHUyaWsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-11-01T13:00:09.000Z",
     "updated": "2022-11-01T13:00:09.273Z",
     "summary": "ASND Ascendis Pharma PDUFA",
     "description": "2023-04-30 COPENHAGEN, Denmark, Oct. 31, 2022 (GLOBE NEWSWIRE) --  Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food &amp; Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2023. https://www.globenewswire.com/news-release/2022/10/31/2544511/0/en/FDA-Accepts-for-Priority-Review-Ascendis-Pharma-s-NDA-for-TransCon-PTH-in-Adult-Patients-with-Hypoparathyroidism.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-04-30"
     },
     "end": {
      "date": "2023-04-30"
     },
     "iCalUID": "dcl2i1qi6bomu783laekelu2ik@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3336177630070000\"",
     "id": "i9nb7m94e44qongmbdu8bi3b7k",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=aTluYjdtOTRlNDRxb25nbWJkdThiaTNiN2sgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-11-10T14:00:15.000Z",
     "updated": "2022-11-10T14:00:15.035Z",
     "summary": "IONS Ionis Pharmaceuticals, Inc. PDUFA",
     "description": "2023-04-25 NDA for tofersen was accepted and granted priority review by the FDA; Prescription Drug User Fee Act date of April 25, 2023 https://www.prnewswire.com/news-releases/ionis-reports-third-quarter-financial-results-301672361.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-04-25"
     },
     "end": {
      "date": "2023-04-25"
     },
     "iCalUID": "i9nb7m94e44qongmbdu8bi3b7k@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3339806405820000\"",
     "id": "83i47h33415a2igvt7cdue7pvo",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ODNpNDdoMzM0MTVhMmlndnQ3Y2R1ZTdwdm8gNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-12-01T14:00:02.000Z",
     "updated": "2022-12-01T14:00:02.910Z",
     "summary": "REGN Regeneron Pharmaceuticals, Inc. PDUFA",
     "description": "2023-03-30 The FDA target action date is March 30, 2023. https://www.prnewswire.com/news-releases/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholesterol-accepted-for-fda-priority-review-301690183.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-03-30"
     },
     "end": {
      "date": "2023-03-30"
     },
     "iCalUID": "83i47h33415a2igvt7cdue7pvo@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3340843206720000\"",
     "id": "26mbku8ncpfutfqn84kukd2258",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=MjZtYmt1OG5jcGZ1dGZxbjg0a3VrZDIyNTggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-12-07T14:00:03.000Z",
     "updated": "2022-12-07T14:00:03.360Z",
     "summary": "EBS Emergent BioSolutions PDUFA",
     "description": "2023-03-29 The Prescription Drug User Fee Act goal date is March 29, 2023. https://www.globenewswire.com/news-release/2022/12/06/2568056/33240/en/Emergent-BioSolutions-Announces-U-S-FDA-Acceptance-and-Priority-Review-of-Supplemental-New-Drug-Application-for-Over-the-Counter-NARCAN-naloxone-HCl-Nasal-Spray.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-03-29"
     },
     "end": {
      "date": "2023-03-29"
     },
     "iCalUID": "26mbku8ncpfutfqn84kukd2258@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3343262406546000\"",
     "id": "4tckk02qfd4t9k33hkuik18f3c",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=NHRja2swMnFmZDR0OWszM2hrdWlrMThmM2MgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-12-21T14:00:03.000Z",
     "updated": "2022-12-21T14:00:03.273Z",
     "summary": "SGEN SEAGEN INC. PDUFA",
     "description": "2023-04-21 The agency set a Prescription Drug User Fee Act (PDUFA) goal date for each application of April 21, 2023. http://www.businesswire.com/news/home/20221220005198/en/Seagen-Astellas-and-Merck-Announce-FDA-Acceptance-of-sBLAs-for-PADCEV%C2%AE-enfortumab-vedotin-ejfv-with-KEYTRUDA%C2%AE-pembrolizumab-for-the-First-Line-Treatment-of-Certain-Patients-With-Locally-Advanced-or-Metastatic-Urothelial-Cancer",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-04-21"
     },
     "end": {
      "date": "2023-04-21"
     },
     "iCalUID": "4tckk02qfd4t9k33hkuik18f3c@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
        "kind": "calendar#event",
        "etag": "\"3356740818750000\"",
        "id": "63e3bkldla2s7aandssl24mrt4",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=NjNlM2JrbGRsYTJzN2FhbmRzc2wyNG1ydDQgZXZnb2hvdm0ybTN0dXZxYWtkZjRoZmVxODRAZw&ctz=America/Los_Angeles",
        "created": "2023-03-09T14:00:09.000Z",
        "updated": "2023-03-09T14:00:09.375Z",
        "summary": "AZN AstraZeneca PLC FDA AdCom",
        "description": "2023-04-28 The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will discuss supplemental new drug application (sNDA) 208558/S–025, for LYNPARZA (olaparib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for this product is in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-28-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04282023",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.com",
         "displayName": "Adcom",
         "self": true
        },
        "start": {
         "date": "2023-04-28"
        },
        "end": {
         "date": "2023-04-28"
        },
        "iCalUID": "63e3bkldla2s7aandssl24mrt4@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       },
       {
        "kind": "calendar#event",
        "etag": "\"3360535231830000\"",
        "id": "i0sle02r326skdigjlln8qbfbg",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=aTBzbGUwMnIzMjZza2RpZ2psbG44cWJmYmcgZXZnb2hvdm0ybTN0dXZxYWtkZjRoZmVxODRAZw&ctz=America/Los_Angeles",
        "created": "2023-03-31T13:00:15.000Z",
        "updated": "2023-03-31T13:00:15.915Z",
        "summary": "OTSKY Otsuka Holdings Co., Ltd. FDA AdCom",
        "description": "2023-04-14 The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committees will discuss supplemental new drug application (sNDA) 205422 s009, efficacy supplement for REXULTI (brexpiprazole) tablets, submitted by Otsuka Pharmaceutical Company, Ltd., and Lundbeck, Inc., for the proposed treatment of agitation associated with Alzheimer’s dementia. https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-14-2023-joint-meeting-psychopharmacologic-drugs-advisory-committee-and-peripheral-and-central",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.com",
         "displayName": "Adcom",
         "self": true
        },
        "start": {
         "date": "2023-04-14"
        },
        "end": {
         "date": "2023-04-14"
        },
        "iCalUID": "i0sle02r326skdigjlln8qbfbg@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       }
   ]